Huntington's market set to reach $918 million by 2030 in 3MM, says analyst

9 July 2021

The Huntington’s disease (HD) market is projected to grow at a Compound Annual Growth Rate (CAGR) of 13.8%, reaching $917.7 million by 2030 across the three major markets (3MM; the USA, Germany, and the UK).

The major driver of this growth will be the launches of two novel symptomatic pipeline agents in this market, Neurocrine Biosciences’ (Nasdaq: NBIX) Ingrezza (valbenazine) and Prilenia Therapeutics’ Huntexil (pridopidine), says data and analytics company GlobalData.

The company’s report, ‘Huntington’s Disease: Opportunity Assessment and Forecast to 2030’, states that the HD market is currently dominated by generics and off-label drugs, with the exception of Teva Pharmaceutical Industries’ (NYSE: TEVA) Austedo (deutetrabenazine) that is only available in the USA. This has resulted in limited treatment costs and market sales. Therefore, the introduction of two relatively expensive pipeline products into this stagnant market will have a significant impact.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK